In addition, the combination of the two drugs strongly reduced HiMYC cell numbers (Figure S3) and the ability of these cells to form colonies in a clonogenic assay (Figure 6C), suggesting that ABCC1 inhibition can sensitize prostate cancer cells to the effect of Docetaxel. Here, ABCC1 is linked to prostate carcinoma.